Zydus Cadila has received the final approval from the Us Food and Drug Administration (USFDA) to market Bumetanide Tablets USP in the strengths of 0.5 mg, 1 mg, and 2 mg. It is used to treat edema associated with congestive heart failure, hepatic and renal disease, including the Nephrotic Syndrome. The tablets will be manufactured at the group’s manufacturing facility at Baddi.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
